vs
GE医疗（CCRN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
GE医疗的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$236.8M vs $207.3M），GE医疗净利率更高（-35.0% vs -62.0%，领先27.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -23.6%），GE医疗自由现金流更多（$16.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -21.0%）
GE医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，品牌标识为GE HealthCare。公司主要业务分为四大板块：包含分子影像、CT、磁共振、妇科筛查及X光设备的医学影像业务、超声业务，以及聚焦远程患者监测、麻醉呼吸护理、心脏诊断、婴幼儿护理的患者护理解决方案业务，此外还开展医药相关业务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CCRN vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $236.8M | $207.3M |
| 净利润 | $-82.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -30.2% | -54.7% |
| 净利率 | -35.0% | -62.0% |
| 营收同比 | -23.6% | 25.9% |
| 净利润同比 | -2109.7% | 3.5% |
| 每股收益（稀释后） | $-2.56 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $236.8M | $207.3M | ||
| Q3 25 | $250.1M | $159.9M | ||
| Q2 25 | $274.1M | $166.5M | ||
| Q1 25 | $293.4M | $139.3M | ||
| Q4 24 | $309.9M | $164.6M | ||
| Q3 24 | $315.1M | $139.5M | ||
| Q2 24 | $339.8M | $147.0M | ||
| Q1 24 | $379.2M | $108.8M |
| Q4 25 | $-82.9M | $-128.6M | ||
| Q3 25 | $-4.8M | $-180.4M | ||
| Q2 25 | $-6.7M | $-115.0M | ||
| Q1 25 | $-490.0K | $-151.1M | ||
| Q4 24 | $-3.8M | $-133.2M | ||
| Q3 24 | $2.6M | $-133.5M | ||
| Q2 24 | $-16.1M | $-131.6M | ||
| Q1 24 | $2.7M | $-170.7M |
| Q4 25 | — | — | ||
| Q3 25 | 20.4% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 20.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 20.4% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | -30.2% | -54.7% | ||
| Q3 25 | -2.4% | -106.9% | ||
| Q2 25 | -2.1% | -64.8% | ||
| Q1 25 | -0.3% | -102.6% | ||
| Q4 24 | -1.1% | -74.3% | ||
| Q3 24 | 0.9% | -94.6% | ||
| Q2 24 | -5.7% | -79.1% | ||
| Q1 24 | 0.8% | -151.9% |
| Q4 25 | -35.0% | -62.0% | ||
| Q3 25 | -1.9% | -112.8% | ||
| Q2 25 | -2.4% | -69.0% | ||
| Q1 25 | -0.2% | -108.5% | ||
| Q4 24 | -1.2% | -80.9% | ||
| Q3 24 | 0.8% | -95.7% | ||
| Q2 24 | -4.7% | -89.5% | ||
| Q1 24 | 0.7% | -156.8% |
| Q4 25 | $-2.56 | $-1.28 | ||
| Q3 25 | $-0.15 | $-1.81 | ||
| Q2 25 | $-0.20 | $-1.17 | ||
| Q1 25 | $-0.02 | $-1.57 | ||
| Q4 24 | $-0.13 | $-1.34 | ||
| Q3 24 | $0.08 | $-1.40 | ||
| Q2 24 | $-0.47 | $-1.52 | ||
| Q1 24 | $0.08 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $108.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $322.8M | $-80.0M |
| 总资产 | $449.0M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $108.7M | $421.0M | ||
| Q3 25 | $99.1M | $202.5M | ||
| Q2 25 | $81.2M | $176.3M | ||
| Q1 25 | $80.7M | $127.1M | ||
| Q4 24 | $81.6M | $174.0M | ||
| Q3 24 | $64.0M | $150.6M | ||
| Q2 24 | $69.6M | $480.7M | ||
| Q1 24 | $5.2M | $112.3M |
| Q4 25 | $322.8M | $-80.0M | ||
| Q3 25 | $408.1M | $9.2M | ||
| Q2 25 | $412.2M | $151.3M | ||
| Q1 25 | $418.2M | $144.2M | ||
| Q4 24 | $419.0M | $255.0M | ||
| Q3 24 | $424.7M | $346.8M | ||
| Q2 24 | $433.3M | $432.4M | ||
| Q1 24 | $462.4M | $140.3M |
| Q4 25 | $449.0M | $1.5B | ||
| Q3 25 | $538.2M | $1.2B | ||
| Q2 25 | $553.8M | $1.3B | ||
| Q1 25 | $576.2M | $1.3B | ||
| Q4 24 | $589.3M | $1.5B | ||
| Q3 24 | $597.4M | $1.5B | ||
| Q2 24 | $602.9M | $1.6B | ||
| Q1 24 | $648.4M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $16.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 6.8% | -48.6% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $40.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $18.2M | $-99.8M | ||
| Q3 25 | $20.1M | $-91.4M | ||
| Q2 25 | $4.2M | $-108.3M | ||
| Q1 25 | $5.7M | $-166.5M | ||
| Q4 24 | $24.2M | $-79.3M | ||
| Q3 24 | $7.5M | $-67.0M | ||
| Q2 24 | $82.4M | $-77.0M | ||
| Q1 24 | $6.0M | $-190.7M |
| Q4 25 | $16.1M | $-100.8M | ||
| Q3 25 | $17.9M | $-92.7M | ||
| Q2 25 | $2.3M | $-110.7M | ||
| Q1 25 | $3.8M | $-167.8M | ||
| Q4 24 | $21.7M | $-79.5M | ||
| Q3 24 | $6.3M | $-68.6M | ||
| Q2 24 | $79.6M | $-79.0M | ||
| Q1 24 | $3.8M | $-193.9M |
| Q4 25 | 6.8% | -48.6% | ||
| Q3 25 | 7.2% | -58.0% | ||
| Q2 25 | 0.8% | -66.5% | ||
| Q1 25 | 1.3% | -120.5% | ||
| Q4 24 | 7.0% | -48.3% | ||
| Q3 24 | 2.0% | -49.2% | ||
| Q2 24 | 23.4% | -53.7% | ||
| Q1 24 | 1.0% | -178.2% |
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.6% | 1.0% | ||
| Q4 24 | 0.8% | 0.1% | ||
| Q3 24 | 0.4% | 1.2% | ||
| Q2 24 | 0.8% | 1.4% | ||
| Q1 24 | 0.6% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
